NPC
ABUS icon

National Planning Corporation’s Arbutus Biopharma ABUS Stock Holding History

National Planning Corporation’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-2,250
Closed -$33.5K – 652
2014
Q4 		$33.5K Buy
+2,250
New +$38.8K ﹤0.01% 1469

Other funds holding ABUS

QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BRC
Blue Ridge Capital New York $215M AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return

National Planning Corporation's ABUS Position: Q1 2015 in Review

National Planning Corporation sold out of Arbutus Biopharma (ABUS) in Q1 2015, closing a stake of 2,250 shares — an estimated $33.5K sold.

National Planning Corporation first reported a position in ABUS in Q4 2014 and held it in 1 quarter. The position peaked at $33.5K in Q4 2014. 77 funds tracked by Wall St. Rank hold ABUS as of Q1 2015.

  • National Planning Corporation reported no remaining Arbutus Biopharma position as of Q1 2015 after selling out during the quarter.
  • National Planning Corporation sold 2,250 Arbutus Biopharma shares in Q1 2015, an estimated $33.5K.
  • National Planning Corporation first reported a position in Arbutus Biopharma in Q4 2014 and held it in 1 quarter.
  • National Planning Corporation's Arbutus Biopharma position peaked at $33.5K in Q4 2014.
  • 77 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2015.

Based on National Planning Corporation's 13F filing for Q1 2015, filed 12 May 2015.